

For antibody-based drug research FcResolv[™] NOG

Severe immunodeficient mouse with mouse FcyR knocked out Attenuates false positive and false negative results caused by mouse innate immune cells



VS // In-Vivo Science Inc.


Useful for studying antitumor effects of immune checkpoint blocking antibodies FcyR deficient



Nivolumab

Tumor growth inhibition by nivolumab:

Growth of HSC4, HCC827, and NCI-H1975 tumors was strongly suppressed or rejected by Nivolumab in huNOG-FcgR KO mice, but not in conventional huNOG mice.



Pathological analysis by immunohistochemistry (IHC) :

- HSC4, NCI-H1975, and HCC827 tumors transplanted into nivolumab-treated huNOG-FcgR KO mice showed enhanced human CD4+ and CD8+ T cell infiltration, but not RKO.
- In conventional huNOG mice, only a small number of human T cell infiltrates were observed after nivolumab administration.
 Katano et al. Scientific reports 2021

In-Vivo Science Inc.

Contact: In-Vivo Science Inc.

WEB : In-Vivo Science Inc. (invivoscience.com)

TEL:+81-44-201-8518

FAX:+81-44-201-8519

e-mail : sales@invivoscience.com